ACADEMIC

Jian Zhang, MD. PhD., is a Professor in Medical School of Southern University of Science and Technology (SUSTech). Dr Zhang received his MD degree from Department of Medicine Tianjin Medical University, China, in 1986, and a Ph.D. in Pathology from the University of Michigan, Ann Arbor, Michigan, in 2001. After a three-year postdoctoral fellowship at the University of Michigan, Dr. Zhang served as a tenure-track Assistant Professor at the University of Pittsburgh and the University of Michigan, Department of Internal Medicine and the University of Michigan Comprehensive Cancer Center. In 2011, his team returned to China and set up the 1st Center for Translational Medicine in Southwest of China. From 2011-2016, he serves as a professor and director for Key Laboratory of Longevity and Aging-related Diseases, Ministry of Education, China.  In 2016, he joined the SUSTech as the deputy director of medical school planning office.  His research interests have been focused on the study of aging-related diseases including aging-associated cancer biology. He has expertise in tumor microenvironment, chemoresistance and metastasis. He is the author/co-author of over 100 peer-reviewed publications and a reviewer for Department of Defense panel of cancer pathobiology, Cancer Research UK program, and Australia Prostate Cancer Research Program and Key Projects in National Science Foundation and “Changjiang Scholar” China.  From 2015 to 2017, he served as the associate editor for “Medical Oncology”.

EDUCATION

1981-1986: Bachelor, Department of Clinical Medicine, Tianjin medical university

1997-1998: Master, Old Dominion University & East Virginia Medical School, Immunology

1998-2001: Doctor, University of Michigan, Pathology

EXPERIENCE

1986.8-1995.1 Resident/Attending Doctor, Tianjin Third hospital/Tianjin Institute of Geriatrics

1995.1-1996.8 Visiting Scholar, Institute of Geriatrics, University of Wisconsin-Madison,  supporting by the fellowship of the World Health Organization

1996.8-1998.8 Visiting Research Scientist, Center for geriatric research at eastern Virginia medical school

1998.8-2004.6 PhD student/Researcher, University of Michigan school of medicine

2004.7-2010.12 Assistant Professor (Tenure track), school of medicine, university of Pittsburgh and university of Michigan

2011.1-2016. 7 Director/Professor, Key laboratory of longevity and geriatric diseases, Ministry of Education, school of translational medicine, Guangxi medical university,

2016.3- Adjunct Professor, university of Pittsburgh, school of medicine

2016.7- Professor, school of medicine, southern university of science and technology

RESEARCH INTERESTS

Translational research on discovery of tumor biomarkers and validation of cancer therapeutic targets

Chemoresistance, relapse and tumor metastasis

Aging and cancer

HONORS AND AWARDS

2014-Experts with special government allowance from the state council

2013-National Talents Engineering, young and middle-aged experts with outstanding contributions

2013-International lecturer, Society for Basic Urology Research (SBUR)

2012-Outstanding national scientists and technicians

2011-Bagui Scholars of Guangxi Autonomous Region, counselor to the government of Guangxi Autonomous Region

2007-Mentoring Dr. Yi Lu, Young Investigator Travel Award, ASBMR

2005-Mentoring Dr. Yi Lu, Scholar-in-Training Award, AACR

2003-Scholar-in-Training Award, AACR

2003- Plenary Poster Award of 25^th Annual Meeting of American Society for Bone and Mineral Research

2002-Alice L. Jee Memorial Young Investigator Award

2000-Plenary Poster Award of 22^nd Annual Meeting of American Society for Bone and Mineral Research

1994- Fellowship Award, World Health Organization (WHO)

BIBLIOGRAPHY

1. Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235-1244, 2001.

2. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Antioxidant & Redox Signaling. 3:493-504, 2001.

3. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256-1263, 2002.

4. Zhang J, J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone. Cancer Res. 63:7883-90, 2003

5. Zhang J, Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo. 59:360-9, 2004

6. Zhang J, Dai J, Lu Y, Yao Z, O’Brein C, Qi W, Hall D, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. Experimental Gerontology. 39:239-247, 2004

7. Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J*. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. 66:1311-8, 2006

8. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J*. Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption. Cancer Res, 67:3646-53, 2007 (影响因子 6)

9. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, and Zhang J*. CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 101:676-685, 2007

10. Lu Y, Yao Z, and Zhang J*. Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment. Chin J of Biochem and Molecul Biol, 23(3):167-171, 2007

11. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J*. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.   Int J of Cancer. 121:724-733, 2007

12. Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J*. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation. Mol Cancer Therapeutics, 7(10):3203-11, 2008

13. Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, and Zhang J*. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res, 6(4): 546-54, 2008

14. Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, and Zhang J*. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2):161-9, 2009

15. Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, and Zhang J*. MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia, 11(3):228-236, 2009

16. Zhang J, Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1):41-8, 2010

17. Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J Natl Cancer Inst. 102(8):522-8, 2010

18. Zhang J*, Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011

19. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.

20. Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET, Zhang J*, Deng J*，Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. Plos One. 9(6):e100394, 2014

21. Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J*. Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer, 2014, 5; 473-86 (影响因子13)

22. Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou* , and Zhang J*. Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759-7714.12294

23. Yu Zhu, Chunlin Zou, Zhe Zhang, Chaonan Qian, Xin Yang, Junlin Shi, Yudui Xia, Zhang J*, Yi Lu*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression. Tumor Biology, 2015, 36(11):8811-8.

24. Sha He, Yi Lu, Xia Liu, Xin Huang, Evan Keller, Chao-Nan Qian*, Zhang J *; Wnt3a: function and implication in cancer. Chinese Journal of Cancer, 2015, 34(3):50.

25. Lihui Wang, Yanli He, Weijun Liu, Shengbin Bai, Lei Xiao, Jie Zhang, Saravana M. Dhanasekaran, Zhuwen Wang, Shanker Kalyana-Sundaram, O. Alejandro Balbin, Sudhanshu Shukla, Yi Lu, Jules Lin, Rishindra M. Reddy, Philip W. Carrott, Jr., William R. Lynch, Andrew C. Chang, Arul M. Chinnaiyan, David G. Beer*, Zhang J*, Guoan Chen*. Non-coding RNA LINC00535 promotes lung adenocarcinoma progression via the Akt pathway. Oncotarget, 7(10):11487-99，

26. Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lu*, Zhang J*. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016, 49:838-846.

27. Yeguo Yang, Yi Lu, Lihui Wang, Atsushi Mizokami, Evan T. Keller, Zhang J*, Jiejun Fu*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27. Oncology Reports, 2016, 36:559-566.

28. Yang Liu, Yi Chai, Zhang J*, and Junwei Tang*. A function variant at miR-501 alters susceptibility thepatocellular carcinoma in a Chinese han population. Cell Physiol Biochem, 38(6):2500-8, 2016.

29. Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J, Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget, 2016, Oct 18;7(42):68140-68150.

30. Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 2017; 36(1):17.

31. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D*, Deng J*, and Zhang J*. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep. 2017; 7: 41656.

32. Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* and Jian Zhang*. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017; 36:35

33. Yutao Gao, Xia Liu, Ting Li, Luwei Wei, Antai Yang, Yi Lu, Jian Zhang, Li Li, Sumei Wang and Fuqiang Yin. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncology Reports. 2017; DOI: 10.3892/or.2017.5534

34. Jinlu Dai, Yi Lu, Hernan Roca, Jill M. Keller, Jian Zhang, Laurie K. McCauley and Evan T. Keller. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer, 2017; 36:29